about
Immunoregulation in human American leishmaniasis: balancing pathology and protectionIdentifying vaccine targets for anti-leishmanial vaccine developmentCD8+ T cells as a source of IFN-γ production in human cutaneous leishmaniasis.CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists.CD8+ T cells in situ in different clinical forms of human cutaneous leishmaniasis.Leishmaniasis Vaccine: Where are We Today?TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia)Protective and pathological functions of CD8+ T cells in Leishmania braziliensis infection.In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccineBiological responses to spider silk-antibiotic fusion protein.Proteins of Leishmania (Viannia) shawi confer protection associated with Th1 immune response and memory generation.Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana.Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example.Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasisProspects for the control of neglected tropical diseases by mass drug administration.Immunological perspectives of leishmaniasis.Human immunodeficiency virus and leishmaniasis.Immune responses during cutaneous and visceral leishmaniasis.Immunity to visceral leishmaniasis: implications for immunotherapy.The Role of CD4 and CD8 T Cells in Human Cutaneous Leishmaniasis.Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.Differential Recruitment of Dendritic Cells Subsets to Lymph Nodes Correlates with a Protective or Permissive T-Cell Response during Leishmania (Viannia) Braziliensis or Leishmania (Leishmania) Amazonensis Infection.Immunization with Leishmania vaccine-alum-BCG and montanide ISA 720 adjuvants induces low-grade type 2 cytokines and high levels of IgG2 subclass antibodies in the vervet monkey (Chlorocebus aethiops) model.Characterization of chronic cutaneous lesions from TNF-receptor-1-deficient mice infected by Leishmania major.Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis.Mining the Proteome of Leishmania donovani for the Development of Novel MHC Class I Restricted Epitope for the Control of Visceral Leishmaniasis.Cytotoxic activity in cutaneous leishmaniasis.Toll-like receptors 2, 4, and 9 expressions over the entire clinical and immunopathological spectrum of American cutaneous leishmaniasis due to Leishmania(V.) braziliensis and Leishmania (L.) amazonensis.Leishmania vaccines: from leishmanization to the era of DNA technologyIn Vivo Biological Responses to Silk Proteins Functionalized with Bone Sialoprotein
P2860
Q26850280-FAAB2EDE-BBC9-4D80-8B1C-EE12C71F03D2Q33693899-29ACC25F-079F-47F2-B734-B77998A1DB2EQ33725704-4EDF8649-A19B-48D5-A964-18606CEE0703Q33745224-1F66BB4E-4F8D-4835-9D3C-DB12A574364EQ33926776-EFA8CA52-9994-4214-9801-7E8CB267DD9FQ33929859-7DA862B1-F149-4B6D-8943-0A474A3D079BQ33939303-9F434761-44BD-4CC2-9312-A649652E4F32Q35098224-ADB1359D-835B-429B-8957-57AEEC8C9EF2Q35198753-853A44FB-B346-4CF6-9153-4EA96D6DA417Q35326248-7E1EA8F6-F682-4BD3-A094-E5F514A487FAQ35910841-FEE395B2-F40A-416E-8833-0DE29B10F62BQ35927732-A0F65408-3B32-48EC-B3B8-CE2590E2B0CFQ36523002-DD823737-1A3C-4261-943A-4607E045D650Q37118101-CAFC9849-F88E-40E3-950D-58BD0941151CQ37251607-B5693F47-B975-4EF3-B8BB-4871C9E93D9DQ37557676-7FB04921-60EB-42A4-B5CB-1CF7165C74E6Q37770420-DB15B062-E28B-4E14-BA3C-6C17C9AC4C8FQ37798456-D233C59D-1E25-45D6-9C0A-EE81981B1C67Q38235268-531B6139-4950-4042-96B4-222382330056Q38243220-96354D3D-4874-4658-B9AF-CA21232EA9B1Q38261036-BC73BC83-16CB-47D7-9644-9E6863970C89Q38342966-3058B490-562A-49AC-B43B-9E305362C974Q38933476-FE8B7B52-6081-4270-8295-7230B1C221E5Q39284812-AB74DC6A-BB47-42C3-9482-7FB4D5A6E146Q39724846-06A15DE4-897F-4A17-B23B-F7F2AAD93AE2Q40061497-D91B9F57-1F11-41BB-A314-B76D4168F727Q40171180-B5AF69E6-D757-4494-8872-6FE4F8B8E27FQ46270906-83789C21-5E25-4A88-9153-A2EA2974F575Q54255382-10E0EC32-CB90-48CB-BB8C-4DBE5D160A43Q56157155-E1FD7C13-6DC4-42A5-A3AD-03568C2C02C3Q57171268-8EF64E42-243C-44B5-AB43-8E3741F98DC5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CD8 cytotoxic T cells in cutaneous leishmaniasis.
@en
CD8 cytotoxic T cells in cutaneous leishmaniasis.
@nl
type
label
CD8 cytotoxic T cells in cutaneous leishmaniasis.
@en
CD8 cytotoxic T cells in cutaneous leishmaniasis.
@nl
prefLabel
CD8 cytotoxic T cells in cutaneous leishmaniasis.
@en
CD8 cytotoxic T cells in cutaneous leishmaniasis.
@nl
P2860
P1433
P1476
CD8 cytotoxic T cells in cutaneous leishmaniasis.
@en
P2093
P2860
P304
P356
10.1111/J.1365-3024.2007.00991.X
P577
2007-12-01T00:00:00Z